Dynamic changes in
Ovarian Cancer
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
There is a lack of biomarkers to predict outcome following initial treatment in patients with high-grade ovarian cancer. We hypothesized that monitoring
Identifiants
pubmed: 39313297
pii: ijgc-2024-005581
doi: 10.1136/ijgc-2024-005581
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MK: advisory boards/honoraria: GSK, AstraZeneca; travel, accommodations: Pfizer, GSK, Eisai. ND: travel, accommodations: GSK; advisory boards/honoraria: GSK, AstraZeneca, MSD, Clovis Oncology, EISAI. KH: shareholder/stockholder/stock options, full/part-time employment: Inivata. ER: honoraria: AstraZeneca (Inst), Roche (Inst), BMS (Inst), GlaxoSmithKline (Inst), Clovis Oncology (Inst); consulting or advisory role: AstraZeneca; research funding: AstraZeneca (Inst); travel, accommodations, expenses: AstraZeneca, BMS. JBM : honoraria: Jazz Pharmaceuticals, Astellas Pharma; consulting or advisory role: AbbVie, Servier; travel, accommodations, expenses: AbbVie. AL: honoraria (self): Medscape; AZ, Clovis, GSK, Kephren; advisory/consultancy: AZ, Clovis, GSK, Biocad, Ability Pharma, Merck Serono, Tesaro, MSD, Seattle Genetics, Gamamabs, Gritstone; research grant/funding (self): Inivata, Sanofi, AZ, OSE Immuno; travel/accommodation/expenses: AZ, Roche, Clovis, Tesaro. All other authors have declared no conflicts of interest.